// App-Quantinova.ai

: Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study

Researchers

Presenter

  • Katja Weisel

Principal Investigators

  • Philippe Moreau

  • Munci Yagci

  • Alessandra Larocca

  • Abraham S. Kanate

  • Filiz Vural

  • Nicola Cascavilla

  • Supratik Basu

  • Peter Johnson

  • Peter D. Byeff

  • Marek Hus

  • Paula Rodriguez Otero

  • Kosei Matsue

  • Ercan Muelduer

  • Pekka Anttila

  • Patrick Hayden

  • Maria-Theresa Krauth

  • Dina Ben-Yehuda

  • Larisa P. Mendeleeva

  • Shien Guo

  • Lea Purnomo

  • Xin Yu

  • Lara Grote

  • Tsvetan Biyukov

  • Mohamed Zaki

  • Paul Richardson

Medical Centers

  • Department of Hematology, Oncology and Immunology, University Hospital Tuebingen, Tuebingen, Germany

  • National and Kapodistrian University of Athens, Athens, Greece

  • University Hospital Hotel-Dieu, Nantes, France

  • Gazi Universitesi Tip Fakueltesi Hastanesi, Ankara,

  • Ospedale San Giovanni Battista, Torino, Italy

  • Mary Babb Randolph Cancer Center, West Virginia University School of Medicine, Morgantown, WV

  • ege university hospital, Izmir, Turkey

  • PathologyIRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy

  • New Cross Hospital, Wolverhampton, United Kingdom

  • Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom

  • Cancer Center of Central Connecticut, Southington, CT

  • Medical University of Lublin, Lublin, Poland

  • University of Navarra, Pamplona, Spain

  • Department of Medical Oncology, Nagoya Medical Center, Nagoya, Japan

  • Medizinische Universitaet Wien - Wilhelminenspital, Vienna, Austria

  • Helsinki University Central Hospital Cancer Center, Helsinki, Finland

  • St James Hospital Cancer Clinical Trials Office,Dublin,Ierland

  • Universitatsklinik fur Innere Medizin IV, Austria

  • Division of Hematology, Hadassah Ein-Kerem Medical Center, Jerusalem, Israel

  • National Research Center for Hematology, Moscow, Russia

  • Evidera, Waltham, MA

  • Celgene Corporation, Summit, NJ

  • Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

Locations

  • Germany

  • Greece

  • France

  • Turkey

  • Italy

  • United States

  • United Kingdom

  • Poland

  • Spain

  • Japan

  • Austria

  • Finland

  • Ireland

  • Israel

  • Russia

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Bortezomib

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT01734928

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved